Kenneth F. Grossmann
Professor
Department of Oncological Sciences
Huntsman Cancer Institute
United States of America
Biography
Dr. Grossmann received his medical and doctorate degrees from the Oregon Health Sciences University (OHSU) in Portland Oregon. He completed his residency training in internal medicine at OHSU. As a resident, Dr. Grossmann was awarded the John S. Miller Teaching Award by the graduating medical students in 2005– an award given to the most gifted educator among all interns. During his subspecialty training in medical oncology, Dr. Grossmann completed clinical and research work at OHSU, the University of Utah, and the MD Anderson Cancer Center in Houston Texas where he focused his training on the clinical care of Stage III and IV melanoma patients. In 2009 Dr. Grossmann joined the University of Utah faculty in the Department of Medical Oncology, and advanced to the rank of Assistant Professor in 2011. He is an investigator in the Huntsman Cancer Institute and a member of the Experimental Therapeutics program. Dr. Grossmann is a physician-scientist whose research focus is on understanding the mechanisms of drug resistance, and radiation resistance of melanoma and other cancers. He has published in peer reviewed journals such as Cell, Mutation Research, Diagnostic Cytopathology, and Journal of Translational Medicine. Dr. Grossmann is recognized regionally, nationally, and internationally as a melanoma expert, and as such has been an invited speaker at the Society of Utah Medical Oncology, and at the Future Perspectives in Melanoma Research Meeting in Naples Italy in 2011. He is an active member of the Southwest Oncology Group where he focuses on the design and execution of clinical trials to define the standard of care in melanoma medical oncology. In addition to his work on melanoma, Dr. Grossmann also sees patients with non-melanomatous tumors such as basal cell carcinoma, squamous cell carcinoma of the skin, and cancers of the head and neck. He serves on the National Comprehensive Cancer Network (NCCN) panel for non-melanomatous skin tumors which defines national standards for the oncologic care of these tumor types.
Research Interest
Oncology Internal Medicine Molecular and Medical Genetics
Publications
-
Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT (2016). A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget, 7(39), 64390-64399.
-
Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J (2016). A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer, 122(23), 3641-3649.
-
Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA (2016). Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol, 17(11), 1558-1568.
-
Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossmann K, Higgins SA, Ho AL, Lewis KD, Lydiatt DD, Nehal KS, Nghiem P, Olsen EA, Schmults CD, Sekulic A, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Wong SL, Zic JA, Hoffmann KG, Engh A (2016 May). Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 14(5), 574-597.
-
Sowder JC, Cannon RB, Buchmann LO, Hunt JP, Hitchcock Y, Lloyd S, Grossmann KF, Monroe MM (2017). Treatment-related determinants of survival in early-stage (T1-2N0M0) oral cavity cancer: A population-based study. Head Neck, 39(5), 876-880.
